Cited 7 times in

Cosmetic regional conjunctivectomy with postoperative mitomycin C application with or without bevacizumab injection

Authors
 Seonheui Lee ; Jeongae Go ; Kyoung Yul Seo ; Sooyoung Kim ; Eui Sang Chung ; Hyung Joon Kim ; Sangmoo Lee ; Sunyoung Jang ; Min Lee ; R. Doyle Stulting ; Soolienah Rhiu 
Citation
 American Journal of Ophthalmology, Vol.156(3) : 616~622, 2013 
Journal Title
 American Journal of Ophthalmology 
ISSN
 0002-9394 
Issue Date
2013
Abstract
PURPOSE: To evaluate the complications of cosmetic wide conjunctivectomy and postoperative topical mitomycin C application with or without bevacizumab injection. DESIGN: Cross-sectional cohort study. METHODS: Medical records of 1713 consecutive subjects who received cosmetic wide conjunctivectomy plus postoperative topical mitomycin C by a single surgeon at a single center with or without bevacizumab injection from November 2007 to May 2010 were reviewed. A telephone interview was conducted with 557 of the subjects who could be contacted and agreed to participate in the study. Complications, recurrences, and patient satisfaction were the main outcome measures. RESULTS: A total of 1713 consecutive patients underwent cosmetic wide conjunctivectomy to treat conjunctival hyperemia. Ocular diagnoses in the medical records at the time of surgery included hyperemia (8.8%), pterygium (14.0%), dry eye (3.5%), pinguecula (1.5%), and conjunctival disorder (23.3%). For the remaining 48.9% of subjects, the diagnosis was not mentioned, or the surgical procedure was for cosmetic purposes. Patients were followed for a mean of 10.9 months (range, 0-30.3 months). The overall complication rate was 82.9%, of which 55.6% were considered severe (fibrovascular conjunctival tissue proliferation, 43.8%; scleral thinning, 4.4%; scleral thinning with calcified plaques, 6.2%; intraocular pressure elevation, 13.1%; diplopia, 3.6%; and recurrence of hyperemic conjunctiva, 28.1%). CONCLUSIONS: Cosmetic wide conjunctivectomy plus postoperative topical mitomycin C with or without bevacizumab injection has a high rate of complications and reoperations.
URI
http://ir.ymlib.yonsei.ac.kr/handle/22282913/88312
DOI
10.1016/j.ajo.2013.01.035
Appears in Collections:
1. 연구논문 > 1. College of Medicine > Dept. of Ophthalmology
Yonsei Authors
사서에게 알리기
  feedback
Link
 http://www.sciencedirect.com/science/article/pii/S0002939413001086
Export
RIS (EndNote)
XLS (Excel)
XML

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Browse